Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 12

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 12
---

Asia Pacific markets (“EM”) in our core sectors have outperformed that of their peers in the global developed markets (“DM”),
as evidenced by the 12-month average return of FTSE indices exhibiting Asia Pacific EM’s outperformance over Global DM for the
17 consecutive months prior to our IPO in the Pharmaceuticals and Biotechnology sector and for the 4 consecutive months prior to the
IPO in the Alternative Energy sector.

We
believe listing an Asian (excluding China, Hong Kong and Macau) company on a major U.S. exchange could lead to even greater performance
than listing on an Asian exchange, potentially due to access to a global investor base, brand awareness to global partners and customers,
and potential opportunities for global expansion of the post-merger operations. Most importantly, we believe that our management team
and board members have the in-house capabilities and connectivity in Asia that will enable us to engage with a target in a culturally
sensitive manner, establish a trusted dialogue, cooperate throughout the de-SPAC process, and provide continued support beyond the Business
Combination. Additionally, as of the time of our IPO, we were one of three SPACs with explicit focus on a potential target domiciled
in Asia (excluding China, Hong Kong, and Macau), and we believe we are the only SPAC with our explicit geographical and industry focus.
We will not pursue or consummate our initial Business Combination with any entity with its principal business operations in China, Hong
Kong or Macau.

In
Asia, businesses have been growing rapidly in the broad sustainable technology market including renewable energy, advanced transportation,
digital transformation, clean industrial process, new materials, and advanced healthcare, along with significant growth in clean technology
adoption. For example, South Korean entities issued an aggregate of $50.8 billion in ESG bonds in 2020, and Japan’s total sustainable
investment increased to $2.9 trillion in 2020, a 32% growth since 2018. We believe the accelerating momentum of sustainability in Asia
will likely reshape the startup ecosystems, preparing many privately held companies for the natural path to becoming a scalable, publicly
traded company.

Breakthrough
technology in life sciences

There
is an increasing focus on the importance of healthcare innovation including the development of novel therapeutics and health technologies
in many developed countries due to a growing aging population. This was further exacerbated by the COVID-19 pandemic. Several Asian countries
are experiencing significant aging populations (e.g